ResMed (NYSE:RMD) Stock Price Expected to Rise, Citigroup Analyst Says

ResMed (NYSE:RMD) had its price objective hoisted by equities researchers at Citigroup from $240.00 to $270.00 in a report released on Friday, Benzinga reports. The firm currently has a “neutral” rating on the medical equipment provider’s stock. Citigroup‘s price target suggests a potential upside of 17.00% from the company’s previous close.

A number of other equities research analysts have also weighed in on RMD. Piper Sandler reduced their target price on shares of ResMed from $233.00 to $225.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. UBS Group restated a “buy” rating and set a $300.00 price objective on shares of ResMed in a report on Tuesday, July 21st. Rothschild & Co Redburn started coverage on ResMed in a research note on Wednesday, August 19th. They issued a “neutral” rating and a $230.00 price objective for the company. Royal Bank Of Canada raised their price target on shares of ResMed from $262.00 to $288.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Robert W. Baird set a $213.00 price objective on shares of ResMed in a report on Friday, August 7th. Seven analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $253.69.

ResMed Stock Performance

Shares of RMD traded down $22.07 during trading hours on Friday, hitting $230.76. The company had a trading volume of 3,441,073 shares, compared to its average volume of 1,302,642. The firm has a market cap of $32.45 billion, a price-to-earnings ratio of 22.12, a PEG ratio of 1.53 and a beta of 0.75. The company has a quick ratio of 2.42, a current ratio of 3.10 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $231.83 and a 200-day moving average of $225.57. ResMed has a 12 month low of $180.26 and a 12 month high of $277.67.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $0.24. ResMed had a net margin of 26.94% and a return on equity of 25.58%. The company had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.39 billion. During the same quarter in the previous year, the business posted $2.55 earnings per share. ResMed’s quarterly revenue was up 5.9% on a year-over-year basis. Equities analysts anticipate that ResMed will post 12.11 EPS for the current fiscal year.

Insider Activity at ResMed

In related news, General Counsel Michael J. Rider sold 400 shares of ResMed stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $255.00, for a total value of $102,000.00. Following the completion of the sale, the general counsel directly owned 12,318 shares in the company, valued at approximately $3,141,090. This trade represents a 3.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 8,000 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total value of $1,800,000.00. Following the transaction, the director directly owned 52,773 shares in the company, valued at $11,873,925. The trade was a 13.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 24,343 shares of company stock valued at $5,396,098 in the last three months. Company insiders own 0.58% of the company’s stock.

Institutional Trading of ResMed

A number of hedge funds and other institutional investors have recently modified their holdings of RMD. American Capital Management Inc. acquired a new stake in ResMed during the 2nd quarter worth about $44,522,000. Hsbc Holdings PLC lifted its stake in ResMed by 17.6% in the 4th quarter. Hsbc Holdings PLC now owns 328,785 shares of the medical equipment provider’s stock valued at $79,321,000 after buying an additional 49,253 shares in the last quarter. BlackRock Inc. acquired a new position in ResMed in the 2nd quarter valued at $2,400,375,000. Polymer Capital Management HK LTD purchased a new position in ResMed in the 2nd quarter worth approximately $972,000. Finally, United Capital Financial Advisors LLC acquired a new position in shares of ResMed during the 2nd quarter valued at about $1,105,000. 54.98% of the stock is owned by hedge funds and other institutional investors.

More ResMed News

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Quarterly results exceeded expectations. ResMed reported fiscal Q1 2027 adjusted earnings of $2.91 per share, above the $2.67 consensus estimate, while revenue rose 5.9% year over year to $1.41 billion, topping the $1.39 billion forecast. Growth was supported by sustained demand for sleep devices, productivity improvements and higher gross margins. ResMed Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Analysts raised their price targets. Royal Bank of Canada increased its target from $262 to $288 and maintained an “outperform” rating. KeyCorp also lifted its target from $267 to $277 and retained an “overweight” rating, signaling continued confidence in ResMed’s long-term growth prospects.
• Positive Sentiment: Shareholder returns remain supported. ResMed declared a quarterly dividend of $0.66 per share, equivalent to $2.64 annually and a yield of approximately 1.1%. ResMed Posts Strong Q1 Results and Shareholder Returns
• Neutral Sentiment: Wells Fargo raised its target but kept an “equal weight” rating. The firm increased its price target from $215 to $250, suggesting valuation upside while stopping short of recommending the stock more aggressively. Wells Fargo Adjusts Price Target on ResMed
• Negative Sentiment: Full-year guidance was unchanged. Although ResMed beat quarterly estimates, management maintained its prior annual outlook. Investors may have been looking for an upgrade following the earnings beat, making the lack of increased guidance a likely reason for the stock’s decline.

ResMed Company Profile

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.